Endo Agrees To Buy Par Pharmaceutical In $8 Billion Deal

Endo International PLC said on Monday it has made a deal to buy privately-held generic-drugs maker Par Pharmaceutical Holdings Inc. in an $8.05 billion takeover. The transaction price is made up of approximately 18 million Endo shares and $6.50 billion in cash. Endo said it has "secured fully committed financing" from Deutsche Bank and Barclays to finance the cash portion of the deal. The board of directors at both pharmaceutical companies have unanimously approved the takeover, and there are no further shareholder approvals required, the companies said. Shares of Endo climbed 3.2% premarket.